Join collection
Hello, welcome to our official website!
互联网保险监管升级 中小险企盼跨区销售险种扩容
2019-01-12

  近日,银保监会下发了《关于继续加强互联网保险监管有关事项的通知》。银保监会表示,正在加快《互联网保险业务监管暂行办法》(以下简称《暂行办法》)的修订工作,在新的规定出台以前,原《暂行办法》继续有效.据悉,《暂行办法》于2015年10月1日起施行,施行期限为3年。

  3年来,随着互联网金融迅猛发展,互联网保险业务也呈现加速发展态势。而随着互联网保险驱动方发生根本变化,保险公司向平台所有者转变,一些新的风险趋势有所冒头,对现有的监管制度提出了挑战。此前,银保监会允许意外险、定期寿险等保险业务可以扩展至未设分公司的省、自治区和直辖市。而此次修订《暂行办法》是否放开更多险种,如重疾险跨区销售成为险企关注的一个焦点。

  互联网保险格局生变,中国互联网保险起步很早,引爆市场的一个标志性事件是,2012年12月国华人寿通过淘宝聚划算平台借助万能险产品创造了三天一亿元的销售神话。2013年国内首家互联网保险公司众安在线财产保险获得原保监会批准成立,此后中国互联网保险进入高速发展阶段,互联网保险的保费几乎每年上一个台阶。2015年以来,随着互联网保险驱动方发生根本变化,一些新的问题和风险趋势有所冒头,对现有的监管制度和监管环境提出了挑战。

  如第三方网络平台数量巨大,新媒体、新技术参与程度较高,对保险业务手续费、经营流程、资金收付等进行深度掌控,通过与保险公司的业务合作,间接受保险监管部门监管,不受保险监管部门直接或实质性监管。这导致保险监管规定的信息披露要求、资金收付要求、手续费支付要求等往往在业务实践中难以得到有效的贯彻落实,带来较大的合规风险。

  某些在线平台暗藏“搭售”,通过默认勾选的方式销售一些保险产品,未明确列明承保主体或代理销售主体,未完整披露保险产品条款等相关重要信息,侵害了消费者的知情权、自主选择权等。

  中小保险公司在目前互联网保险环境下亦生存艰难。从目前的格局来看,保费仍然明显向大公司集中。据中保协的数据,2018年上半年,保费规模*大的8家保险公司累计实现互联网财险保费收入235.70亿元,占该市场的份额为72.21%。

  “中小公司互联网保险业务批下来也没法活,在现在这个环境,只要一做业务就亏。前三大保险公司占62%的互联网保险份额,*后39家小的保险公司在保费环节每家不足10亿元,这个数字触目惊心。”某中小保险公司高管感叹。

  同时,互联网保险的内涵与外延发生了很多变化,由作为渠道或场景销售保险为主逐渐过渡到保险科技赋能保险的内涵。而《暂行办法》很大程度上还是沿用*早的互联网保险定义,以通过互联网渠道销售保险产品为主来衡量和评定,需要结合新形势和环境进行修改,提升监管的适应性。

  记者获悉,近日银保监会下发《关于继续加强互联网保险监管有关事项的通知》,其重申2015年原保监会发布《暂行办法》以来,互联网保险业务持续健康发展,服务能力不断增强。银保监会表示,正在加快《暂行办法》的修订工作,在新的规定出台以前,《暂行办法》继续有效。

  一位不愿具名的保险监管人士表示,既要提升监管的适应性,也要保持监管的稳定性。对互联网保险监管采取相对开放的态度,对于互联网保险作业模式与原有监管规则之间的冲突,不能简单从合规的层面予以否定,应该从更深层面查找规则的逻辑基础,以风险防范为*终目的,寻求规则适应与鼓励创新之间的平衡。

“原有监管规则被打破以后,新的规则要及时跟上,对监管来说,守住风险底线是硬道理。”该保险监管人士说。

  跨区销售险种引关注

  银保监会在文件中表示,其正在积极推进互联网保险监管的各项工作,要求各保险机构要切实加强产品创新能力、风险管控能力、客户服务能力建设,要求保险机构认真落实互联网保险业务经营区域和信息披露有关要求,强化保险消费者保护,确保互联网保险业务合规经营。

  在《暂行办法》中,原保监会允许保险代理公司和保险经纪公司在具备销售互联网保险的条件和完成互联网保险备案之后,即可以借助互联网销售保险产品。保险公司也可以自建互联网渠道和借助完成互联网备案的互联网平台销售保险。

  特别是原保监会在《暂行办法》中提出:“保险公司在具有相应内控管理能力且能满足客户服务需求的情况下,可将下列险种的互联网保险业务经营区域扩展至未设立分公司的省、自治区、直辖市:(一)人身意外伤害保险、定期寿险和普通型终身寿险;(二)投保人或被保险人为个人的家庭财产保险、责任保险、信用保险和保证保险;(三)能够独立、完整地通过互联网实现销售、承保和理赔全流程服务的财产保险业务;(四)中国保监会规定的其他险种”。

  目前,市场上有超过100家保险公司开展了互联网保险业务,特别是中小保险公司希望借助互联网渠道实现跨越式发展,所以中小保险公司希望银保监会放开更多的险种跨区销售。

  有知情人士透露,此前银保监会对互联网保险监管办法征求意见。不过,目前并未见银保监会公开发布新的互联网保险监管办法征求意见稿。事实上,记者在采访中了解到,中小寿险公司希望放开重疾险、分红险、年金险、万能险和投连险等产品全国销售。而中小财险公司则希望放开重疾险(包括百万医疗之类的健康险产品)、车险等产品全国销售。

  有小型保险公司人士认为,可以放开重疾险(包括百万医疗产品)、年金险、车险等更多产品跨区销售,像重疾险、年金险这类产品其实理赔服务不多,而且第三方服务公司很多,保险公司完全可以交给第三方服务公司来做;而车险跨区销售,此前众安保险、泰康在线已经进行了尝试,也并未引起市场本质的变化,而且中保车服也已经成立,完全可以进行更多范围的尝试。

  不过,大型保险公司却并不这么认为,特别是重疾险、车险这类产品属于重服务的产品,放开中小保险公司跨区销售反而会影响保险服务,因为中小保险公司的服务能力跟不上。业内有观点认为,分支机构的数量一定程度上会影响将来健康险理赔便利性,一般开设在非消费者所在地的分支机构对消费者的价值有限,除非该用户未来会移居到该地区生活工作。来源:圈中人


暂无评论!
我要评论 只有购买过该商品的用户才能评论。

Gotham Therapeutics Establishes Advanced Oncology Profiling Cascade with ProQinase to Progress its Portfolio of Epitranscriptomic Drug CandidatesWEDNESDAY, OCTOBER 30, 2019Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, and ProQinase, an early stage drug-discovery company, recently acquired by Malvern/PA-based Reaction Biology Corp., today announced that they have established an array of advanced biochemical and cellular assays to characterize epitranscriptomic-directed compounds.“Establishing tailored target engagement, cell biology, phenotypic, and in-vivo assays to evaluate compounds originating from our three most advanced epitranscriptomic programs in parallel is a crucial next step to develop our broad pipeline towards the clinic,” said Dr. Gerhard Müller, Chief Scientific Officer of Gotham Therapeutics. “By pursuing the full range of the reader-writer-eraser continuum, we are able to focus on targets with the most compelling links to disease and advance those programs in tandem.”“Combining our high proficiency in providing customized solutions as early stage drug-discovery services, including tailor-made biochemical and cell-based assays, with Gotham’s expertise in epitranscriptomics, we were able to establish in a very short time a set of customized enzymatic and cellular assays for compounds addressing three different mRNA-modifying targets,” said Dr. Sebastian Dempe, Chief Executive Officer of ProQinase. “We look forward to supporting Gotham as the company advances its programs into lead optimization and to continued work with the Gotham team assisting the company to advance its broad pipeline in a time-effective manner.”In addition to establishing a tailor-made profiling cascade for compounds from its three most advanced programs, Gotham has also made progress in strengthening its drug discovery engine and developing its candidate base. Gotham previously completed the gene-to-lead phase for its drug discovery project targeting the METTL3/METTL14 complex and established a robust discovery process as a platform for future projects. The company has also generated a library of high-quality compounds tailor-made for accelerated hit generation and hit-to-lead expansion against large parts of the epitranscriptomic target space. This library includes a collection of over 2,000 analogues covering over 80 distinct chemotypes that will be used to further accelerate Gotham’s drug discovery efforts as it expands its pipeline.The original link:https://www.pharmafocusasia.com/news/gotham-therapeutics-establishes-advanced-oncology-profiling-cascade-with-proqinase-to-progress-its-portfolio-of-epitranscriptomic-drug-candidates2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/510934/will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

Gilead and Glympse Bio Announce Strategic Collaboration for Use of Biomarker Technology in NASH Clinical DevelopmentTUESDAY, OCTOBER 29, 2019Gilead Sciences Inc. and Glympse Bio, Inc., today announced that the companies have entered into a strategic collaboration in nonalcoholic steatohepatitis (NASH) clinical development. Glympse Bio’s proprietary synthetic biomarkers – bioengineered to identify stage and progression of disease as well as early detection of treatment response – will be used to determine clinical trial participants’ stage of disease at initial screening and to determine responses to study treatment in Gilead’s NASH clinical program.“We are excited about the opportunity to partner with Glympse Bio to help inform our NASH development program,” said Mani Subramanian, MD, PhD Senior Vice President, Liver Diseases, Gilead Sciences. “By utilizing this innovative technology, we hope to better characterize this complex disease and improve our understanding of how our compounds impact disease progression.”Glympse Bio’s proprietary technology, Glympse Inside™, combines synthetic biomarkers with machine learning approaches to identify the stage and monitor progression of important, complex diseases such as cancer, fibrosis, inflammation, and infections, in real time.“We are very excited about partnering with Gilead, a leader in drug development, to help drive earlier and more favorable outcomes for patients,” said Caroline J Loew, President and CEO, Glympse Bio. “Gilead’s commitment to developing innovative medicines in areas of high unmet medical need aligns with our mission of transforming disease detection and measuring treatment response, all with the goal of helping improve the lives of patients.”information source:pharma focus AsiaThe original link:https:https:https://www.pharmafocusasia.com/news/gilead-and-glympse-bio-announce-strategic-collaboration-for-use-of-biomarker-technology-in-nash-clinical-development2019 Asia-pacific pharma IP Leader Summit:http://en.zenseegroup.com/p/510934/ will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

HistoIndex Announces Global Partnerships To Expand AI-Based Digital Pathology PlatformMONDAY, OCTOBER 28, 2019HistoIndex announces the expansion of its AI-based digital pathology platform towards large-scale NASH preclinical programs for pharmaceutical and biotech companies to achieve quantifiable and reproducible data on therapeutic responses in NASH animal models, and to aid CROs as well as research agencies in validating new models mimicking the NASH disease.Published preclinical studies have demonstrated the use of HistoIndex's fully quantifiable Second Harmonic Generation (SHG) technology as a highly accurate stain-free method that can monitor the efficacy of various therapeutic agents, by quantifying more than 450 NASH-associated parameters in fibrosis, inflammation, ballooning and steatosis. The information of these NASH-associated parameters gathered from the entire liver tissue, provides comprehensive insights on the mechanism of action of the therapeutic agent.  As a drug discovery tool, HistoIndex's SHG-enabled digital pathology platform will allow pharmaceutical and biotech companies to select promising lead candidates for further optimization and make informed decisions in the management of their NASH drug development pipeline.In addition to ongoing NASH clinical trials, HistoIndex is currently involved in multiple preclinical studies, most of which are conducted by major pharmaceutical and biotech companies, medical universities, CROs and research agencies. Notably, HistoIndex has recently entered into a collaboration with the A*STAR's Genome Institute of Singapore (GIS) to validate their in vivo and in vitro NASH models based on Asian-centric clinical data. Says Professor Patrick Tan, Executive Director of the Genome Institute of Singapore (GIS), "At GIS, we conduct our preclinical studies on fatty liver involving data from animal models based on patient-derived transcriptomic data. This has a high translational potential as it helps us to pinpoint new therapeutic targets and their validation. Therefore, using a fully quantitative, reliable and objective pathological evaluation such as HistoIndex's AI-based digital pathology platform is essential to the success of our efforts in therapeutic target discovery."HistoIndex is also a partner with globally-renowned CRO, WuXi Apptec, in advancing their NASH preclinical programs with advanced R&D and smart imaging analysis capabilities. Published study data will be available for discussions during networking opportunities throughout AASLD's The Liver Meeting® in November 2019.  "We are very excited to extend our AI-based SHG platform to preclinical studies to help companies with drug discovery programs select promising lead candidates for further optimization and subsequent clinical development," says Dr Poon Thong Yuen, Chief Executive Officer of HistoIndex. "Our SHG image analysis platform has already been used to analyze the efficacy of a series of promising drug candidates for NASH within various animal models commonly-used by the industry, and we believe these preclinical partnerships will help drive the adoption of our platform significantly."information source:pharma focus AsiaThe original link:https:https://www.pharmafocusasia.com/news/histoindex-announces-global-partnerships-to-expand-ai-based-digital-pathology-platform2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/510934/will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

AVROBIO Receives Orphan-Drug Designation from the U.S. FDA for AVR‑RD‑02 for the Treatment of Gaucher DiseaseFRIDAY, OCTOBER 25, 2019AVROBIO, Inc., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation for the Company’s investigational gene therapy, AVR-RD-02, for the treatment of Gaucher disease. AVR-RD-02 consists of the patient’s own hematopoietic stem cells, genetically modified to express glucocerebrosidase (GCase), the enzyme that is deficient in Gaucher disease. The Company is actively recruiting in Canada for its Phase 1/2 clinical trial of AVR-RD-02, which seeks to evaluate the safety and efficacy of the therapy in patients with Type 1 Gaucher disease.“Under the existing standard of care, patients with Gaucher disease are bound to a lifelong infusion schedule of enzyme replacement therapies, and still experience painful and progressive symptoms such as debilitating musculoskeletal pain and fatigue,” said Birgitte Volck, MD, PhD, President of Research and Development at AVROBIO. “Orphan-drug designation recognizes the unmet need of populations with rare diseases like Gaucher where AVROBIO strives to transform lives by addressing the underlying cause of the disease with a single dose of gene therapy.”Orphan-drug designation is granted by the FDA to drugs and biologics which are intended for the safe and effective treatment, diagnosis or prevention of rare diseases or conditions that affect fewer than 200,000 people in the United States. Orphan-drug designation provides certain incentives, which may include tax credits towards the cost of clinical trials and prescription drug user fee waivers.information source:pharma focus AsiaThe original link:https:https://www.pharmafocusasia.com/news/avrobio-receives-orphan-drug-designation-from-the-us-fda-for-avrrd02-for-the-treatment-of-gaucher-disease2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/510934/will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

FRIDAY, OCTOBER 25, 2019AZTherapies, Inc., a biopharmaceutical company developing therapeutics to extend brain health, today announced the acquisition of Smith Therapeutics, a private biopharmaceutical company with a shared goal of targeting neuroinflammation to treat neurodegenerative disease. Smith Therapeutics’ Founder and Chief Executive Officer Philip Ashton-Rickardt, Ph.D., has joined the senior leadership team at AZTherapies as Senior Vice President of Immunology. Financial terms of the acquisition were not disclosed.Smith Therapeutics’ proprietary research platform focuses on the use of modified T cells to restore a healthy balance of inflammatory and regulatory cells in the brain. To date, Smith has successfully engineered immunosuppressive T regulatory (Treg) cells with Chimeric Antigen Receptors (CARs) targeting brain glial cells. Previous research has demonstrated the ability of Tregs to dampen microglial activity and reduce neuroinflammation in models of neurodegeneration, suggesting their potential utility in the treatment of diseases including Progressive Supranuclear Palsy (PSP), Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), and others.“This acquisition represents a meaningful step forward for us as we continue to strengthen our leadership position in the development of therapies targeting neuroinflammation to stop or slow the progression of neurodegenerative diseases,” said David R. Elmaleh, Ph.D., Founder, CEO, and Chairman of AZTherapies. “We are excited to be working with Philip as we add this cutting-edge technology to our portfolio of innovative programs. An esteemed immunologist and inventor of the technology, Philip brings unparalleled expertise to the company and we look forward to advancing this CAR-Treg program further into IND-enabling studies and into clinical development as rapidly as possible.”Dr. Ashton-Rickardt commented on the acquisition and his appointment: “Our shared rationale of targeting neuroinflammation as the root cause of neurodegenerative disease makes this acquisition a great strategic fit for us. With AZTherapies’ expertise in drug development and clinical trial execution, we believe that together, we are well positioned to advance our CAR-Treg technology and fundamentally change neurodegenerative disease progression.”Prior to launching Smith Therapeutics in 2017, Dr. Ashton-Rickardt was Chair in Immunology at Imperial College London, Visiting Professor, Brigham and Women’s Hospital, Harvard Medical School, and Associate Professor in the Department of Pathology at the University of Chicago. His work has been recognized by his peers through the award of tenure from The University of Chicago and by his fellow citizens as a recipient of the Early Career Award for Scientists and Engineers from President Bill Clinton. He has published more than 65 peer-reviewed papers in more than 30 academic journals (including Cell, Science, Immunity, and Nature Immunology), has served as an editor for several academic journals, and has been a member of grant review boards globally. Dr. Ashton-Rickardt received a B.Sc. in Biochemistry from the University of London, King’s College with honors, a Ph.D. in Molecular Biology from the University of Edinburgh, and completed post-doctoral work at the University of Edinburgh and the Massachusetts Institute of Technology in Molecular Biology and Molecular Immunology, respectively.information source:pharma focus AsiaThe original link:https:https://www.pharmafocusasia.com/news/aztherapies-strengthens-neuroinflammation-targeted-pipeline-through-acquisition-of-smith-therapeutics2019 Asia-pacific pharma IP Leader Summit: http://en.zenseegroup.com/p/510934/will be held in Beijing  on November 14-15, and will attract more than 500 industry experts from domestic and foreign pharmaceutical companies, biotechnology companies, governments, associations, law firms, intellectual property agents and other companies to attend.Official registration and consultation channels:Contact:AnnPhone: 021-65650305Email:Marketing@zenseegroup.comhttp://en.zenseegroup.com/p/510934

About Us
Contact Us
Zensee_Daystar online